Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price was up 31% on Thursday . The company traded as high as C$0.24 and last traded at C$0.19. Approximately 727,200 shares changed hands during trading, an increase of 59% from the average daily volume of 456,000 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Performance
The firm has a fifty day moving average of C$0.09 and a 200-day moving average of C$0.07. The stock has a market capitalization of C$20.91 million, a price-to-earnings ratio of -12.00 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Investing In Automotive Stocks
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- What is the MACD Indicator and How to Use it in Your Trading
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
